1.Definition of mood disorders 2.Ethiology and statistic of mood disorders 3.Mood disorders types
Novel Treatments for Mood Disorders · Novel Treatments for Mood Disorders Michael E. Henry, MD...
Transcript of Novel Treatments for Mood Disorders · Novel Treatments for Mood Disorders Michael E. Henry, MD...
![Page 1: Novel Treatments for Mood Disorders · Novel Treatments for Mood Disorders Michael E. Henry, MD Medical Director Bipolar Clinic and Research Program Director Somatic Therapy Massachusetts](https://reader033.fdocuments.net/reader033/viewer/2022050307/5f6f931ed7321c30e52c4fe2/html5/thumbnails/1.jpg)
www.mghcme.org
Novel Treatments for Mood Disorders
Michael E. Henry, MDMedical Director
Bipolar Clinic and Research ProgramDirector
Somatic Therapy Massachusetts General Hospital
![Page 2: Novel Treatments for Mood Disorders · Novel Treatments for Mood Disorders Michael E. Henry, MD Medical Director Bipolar Clinic and Research Program Director Somatic Therapy Massachusetts](https://reader033.fdocuments.net/reader033/viewer/2022050307/5f6f931ed7321c30e52c4fe2/html5/thumbnails/2.jpg)
www.mghcme.org
Disclosures
My spouse/partner and I have the following relevant financial relationship with a commercial
interest to disclose:
Speaker Sunovion Pharmaceuticals
Consultant ITI Pharmaceuticals
Spouse is an employee of Roche
Pharmaceuticals
![Page 3: Novel Treatments for Mood Disorders · Novel Treatments for Mood Disorders Michael E. Henry, MD Medical Director Bipolar Clinic and Research Program Director Somatic Therapy Massachusetts](https://reader033.fdocuments.net/reader033/viewer/2022050307/5f6f931ed7321c30e52c4fe2/html5/thumbnails/3.jpg)
www.mghcme.org
MDD Statistics
• 12 month prevalence U.S.: 9%
• Mortality from Suicide: 20+ x gen pop
• Increased risk of CV death.
• Economic Costs to U.S: $36.6 Billion
Lepine JP, Briley M. Neuropsychiatr Dis Treat 2011; 7(suppl 1) 3-7.
![Page 4: Novel Treatments for Mood Disorders · Novel Treatments for Mood Disorders Michael E. Henry, MD Medical Director Bipolar Clinic and Research Program Director Somatic Therapy Massachusetts](https://reader033.fdocuments.net/reader033/viewer/2022050307/5f6f931ed7321c30e52c4fe2/html5/thumbnails/4.jpg)
www.mghcme.org
Network Depression Model:
must accommodate defining clinical symptoms
attention-cognition-action
emotion-cognition
integration
arousal-autonomic-circadian
oF11
aCg24
selfmF9/10
salience
reward
PF9
thalcd-vs
Cg25
P40
hippocampus
hth pag/dr
a-ins
am
pCg
moodstatemb-sn
PM6
Mayberg, 2003
![Page 5: Novel Treatments for Mood Disorders · Novel Treatments for Mood Disorders Michael E. Henry, MD Medical Director Bipolar Clinic and Research Program Director Somatic Therapy Massachusetts](https://reader033.fdocuments.net/reader033/viewer/2022050307/5f6f931ed7321c30e52c4fe2/html5/thumbnails/5.jpg)
www.mghcme.org
Depression Model
Adapted from Mayberg, 2003
![Page 6: Novel Treatments for Mood Disorders · Novel Treatments for Mood Disorders Michael E. Henry, MD Medical Director Bipolar Clinic and Research Program Director Somatic Therapy Massachusetts](https://reader033.fdocuments.net/reader033/viewer/2022050307/5f6f931ed7321c30e52c4fe2/html5/thumbnails/6.jpg)
www.mghcme.org
Potential Mechanisms For New Antidepressant Treatments
Monoamines Opioids
Glutamate/GABA
Augmentation
Inflammation /Metabolic Neuromodulation
![Page 7: Novel Treatments for Mood Disorders · Novel Treatments for Mood Disorders Michael E. Henry, MD Medical Director Bipolar Clinic and Research Program Director Somatic Therapy Massachusetts](https://reader033.fdocuments.net/reader033/viewer/2022050307/5f6f931ed7321c30e52c4fe2/html5/thumbnails/7.jpg)
www.mghcme.org
Monoamine Projections
Neurowiki2012 –MAO in depression
![Page 8: Novel Treatments for Mood Disorders · Novel Treatments for Mood Disorders Michael E. Henry, MD Medical Director Bipolar Clinic and Research Program Director Somatic Therapy Massachusetts](https://reader033.fdocuments.net/reader033/viewer/2022050307/5f6f931ed7321c30e52c4fe2/html5/thumbnails/8.jpg)
www.mghcme.org
Norepinephrine
![Page 9: Novel Treatments for Mood Disorders · Novel Treatments for Mood Disorders Michael E. Henry, MD Medical Director Bipolar Clinic and Research Program Director Somatic Therapy Massachusetts](https://reader033.fdocuments.net/reader033/viewer/2022050307/5f6f931ed7321c30e52c4fe2/html5/thumbnails/9.jpg)
www.mghcme.org
Serotonin Modulators
• Gepirone- 5-HT1A partial agonist; metabolite A2 antagonist- Low dose - anxiolytic; Hypoactive Sexual Desire Disorder- High dose –antidepressant; - Twice rejected by FDA
• Min-117- SDRI- Targets “Anxio-Depressive symptoms”.- Phase IIB (2015) -? efficacy
https://fabrekramer.com/company
![Page 10: Novel Treatments for Mood Disorders · Novel Treatments for Mood Disorders Michael E. Henry, MD Medical Director Bipolar Clinic and Research Program Director Somatic Therapy Massachusetts](https://reader033.fdocuments.net/reader033/viewer/2022050307/5f6f931ed7321c30e52c4fe2/html5/thumbnails/10.jpg)
www.mghcme.org
Triple Reuptake Inhibitors(SNDRI’s)
• Ideal Profile: Strong SERT; intermediate NET; and mild DAT inhibition. S. Stahl 2013
• Cocaine
• Phencyclidine
• Ketamine
• Ginkgo biloba extract (EGb761) Wikipedia 2017
![Page 11: Novel Treatments for Mood Disorders · Novel Treatments for Mood Disorders Michael E. Henry, MD Medical Director Bipolar Clinic and Research Program Director Somatic Therapy Massachusetts](https://reader033.fdocuments.net/reader033/viewer/2022050307/5f6f931ed7321c30e52c4fe2/html5/thumbnails/11.jpg)
www.mghcme.org
SNDRI’s
• Amitifadine:-SERT:NET:DAT:12:23:96-Positive - phase IIa trial-Negative - phase IIb/IIIa trial - ? Dosing-Smoking cessation
• Ansofaxine-Prodrug of desvenlafaxine (DA)-SERT:NET:DAT: 4:5:3-Phase III trials underway in China and U.S.
![Page 12: Novel Treatments for Mood Disorders · Novel Treatments for Mood Disorders Michael E. Henry, MD Medical Director Bipolar Clinic and Research Program Director Somatic Therapy Massachusetts](https://reader033.fdocuments.net/reader033/viewer/2022050307/5f6f931ed7321c30e52c4fe2/html5/thumbnails/12.jpg)
www.mghcme.org
Second Generation Antipsychotics -FDA Mood Indications
• Olanzapine- TRD- Mania or Mixed
• Aripiprazole- Mania and Mixed episodes- Augmentation of MDD
• Lurasidone- Bipolar I depression
• Cariprazine- Bipolar I Manic and Mixed episodes- Bipolar I Depression
• Ziprasidone- Bipolar I Manic and Mixed episodes- Bipolar I Adjunct to Li or Valproate
• DSP-1200- Alpha -2, D2, 5-HT2A antagonism- Phase I
![Page 13: Novel Treatments for Mood Disorders · Novel Treatments for Mood Disorders Michael E. Henry, MD Medical Director Bipolar Clinic and Research Program Director Somatic Therapy Massachusetts](https://reader033.fdocuments.net/reader033/viewer/2022050307/5f6f931ed7321c30e52c4fe2/html5/thumbnails/13.jpg)
www.mghcme.org
Opiates and Monamines
Lutz PE, Kieffer BL., Trends Neurosci 2013; 195- 206
![Page 14: Novel Treatments for Mood Disorders · Novel Treatments for Mood Disorders Michael E. Henry, MD Medical Director Bipolar Clinic and Research Program Director Somatic Therapy Massachusetts](https://reader033.fdocuments.net/reader033/viewer/2022050307/5f6f931ed7321c30e52c4fe2/html5/thumbnails/14.jpg)
www.mghcme.org
Opiate Receptors
• Mu- Increased GABA tone on 5-HT neurons
• Kappa- Agonists are potent analgesics- Dysphoria, hallucinations, dissociation- Antagonists reverse learned helplessness.- BDNF
• Delta- BDNF/Neuroprotective- Persistent pain/stress not acute pain
• Opioid Receptor Like 1 (ORL1) -Nociceptin
Dhir A. Expert Opinion on Investigational Drugs; 2016
![Page 15: Novel Treatments for Mood Disorders · Novel Treatments for Mood Disorders Michael E. Henry, MD Medical Director Bipolar Clinic and Research Program Director Somatic Therapy Massachusetts](https://reader033.fdocuments.net/reader033/viewer/2022050307/5f6f931ed7321c30e52c4fe2/html5/thumbnails/15.jpg)
www.mghcme.org
Opiate Candidates
• Buprenorphine
- MOR partial agonist; KOR antagonist
- Used off label for TRD
- Abuse potential
• BTRX – 335140
- Selective K opioid antagonist
- Phase I
![Page 16: Novel Treatments for Mood Disorders · Novel Treatments for Mood Disorders Michael E. Henry, MD Medical Director Bipolar Clinic and Research Program Director Somatic Therapy Massachusetts](https://reader033.fdocuments.net/reader033/viewer/2022050307/5f6f931ed7321c30e52c4fe2/html5/thumbnails/16.jpg)
www.mghcme.org
JNJ-67953964
• Short acting KOR antagonist.
• 30 fold selectivity for k receptors relative to mu and delta OR’s.
• 2017 sold to Janssen (CERC-501)
![Page 17: Novel Treatments for Mood Disorders · Novel Treatments for Mood Disorders Michael E. Henry, MD Medical Director Bipolar Clinic and Research Program Director Somatic Therapy Massachusetts](https://reader033.fdocuments.net/reader033/viewer/2022050307/5f6f931ed7321c30e52c4fe2/html5/thumbnails/17.jpg)
www.mghcme.org
BTRX-246040
• Selective Nociceptin (ORL-1) antagonist.
• Increases Monoamines; enhances neurogenesis; and activates the HPA axis.
• MDD – IIA study did not meet primary or secondary endpoints.
![Page 18: Novel Treatments for Mood Disorders · Novel Treatments for Mood Disorders Michael E. Henry, MD Medical Director Bipolar Clinic and Research Program Director Somatic Therapy Massachusetts](https://reader033.fdocuments.net/reader033/viewer/2022050307/5f6f931ed7321c30e52c4fe2/html5/thumbnails/18.jpg)
www.mghcme.org
Glutamate
![Page 19: Novel Treatments for Mood Disorders · Novel Treatments for Mood Disorders Michael E. Henry, MD Medical Director Bipolar Clinic and Research Program Director Somatic Therapy Massachusetts](https://reader033.fdocuments.net/reader033/viewer/2022050307/5f6f931ed7321c30e52c4fe2/html5/thumbnails/19.jpg)
www.mghcme.org
NMDA
• Ketamine/Esketamine –Approved.
• AV-101: Prodrug; glycine B antagonist.
- Neuroprotective in animal models.
- Phase II trials underway.
• GLYX-13: MoAB, NMDA-glycine partial agonist
- Phase II separated from PBO.
• Apimostinel: NMDA-glycine partial agonist.
Phase II trials of oral agent.
Dhir A. Expert Opinion on Investigational Drugs; 2016
![Page 20: Novel Treatments for Mood Disorders · Novel Treatments for Mood Disorders Michael E. Henry, MD Medical Director Bipolar Clinic and Research Program Director Somatic Therapy Massachusetts](https://reader033.fdocuments.net/reader033/viewer/2022050307/5f6f931ed7321c30e52c4fe2/html5/thumbnails/20.jpg)
www.mghcme.org
NMDA/NR2B/AMPA
Rapastinel
- 2016 Breakthrough Therapy designation
from FDA
- NR2B triggers influx of intracellular calcium
- Increased AMPA
- Phase III trials negative.
![Page 21: Novel Treatments for Mood Disorders · Novel Treatments for Mood Disorders Michael E. Henry, MD Medical Director Bipolar Clinic and Research Program Director Somatic Therapy Massachusetts](https://reader033.fdocuments.net/reader033/viewer/2022050307/5f6f931ed7321c30e52c4fe2/html5/thumbnails/21.jpg)
www.mghcme.org
Combination Medication
• AXS – 05
- Buproprion/dextromethorphan
- DM: NMDA and sigma-1 agonist, SNRI
- Breakthrough Therapy
- Phase III (GEMINI)
![Page 22: Novel Treatments for Mood Disorders · Novel Treatments for Mood Disorders Michael E. Henry, MD Medical Director Bipolar Clinic and Research Program Director Somatic Therapy Massachusetts](https://reader033.fdocuments.net/reader033/viewer/2022050307/5f6f931ed7321c30e52c4fe2/html5/thumbnails/22.jpg)
www.mghcme.org
GABA Modulators
• Ganaxolone- GABA-A Positive allosteric modulator-- Hyperpolarizes- Epilepsy, Anxiety- Phase II Post-Partum Depression
• SAGE-547 - Brexanolone- GABA-A Allosteric modulator- Intravenous- Post partum depression – Approved.
• SAGE 217- Oral formulation- Phase III PPD – positive;- Phase III MDD - underway
![Page 23: Novel Treatments for Mood Disorders · Novel Treatments for Mood Disorders Michael E. Henry, MD Medical Director Bipolar Clinic and Research Program Director Somatic Therapy Massachusetts](https://reader033.fdocuments.net/reader033/viewer/2022050307/5f6f931ed7321c30e52c4fe2/html5/thumbnails/23.jpg)
www.mghcme.org
Genotyping
• Cytochrome P450 Isoenzymes
• SERT (S)
• Antidepressant transport
• Individual Receptors -5-HT1A; 5-HT-2A
• BDNF – Val 66Met – decreased hippocampalvolume
• IL-1b - mRNA levels higher in non-responders.
• IL-6 (rs 7801617) – escitalopram response.
![Page 24: Novel Treatments for Mood Disorders · Novel Treatments for Mood Disorders Michael E. Henry, MD Medical Director Bipolar Clinic and Research Program Director Somatic Therapy Massachusetts](https://reader033.fdocuments.net/reader033/viewer/2022050307/5f6f931ed7321c30e52c4fe2/html5/thumbnails/24.jpg)
www.mghcme.org
Genotyping
FDA: October 31, 2018:
• “… the relationship between DNA variations and the effectiveness of antidepressant medications has never been established.”
• “There are a limited number of cases for which at least some evidence does exist to support a correlation between a genetic variant and drug levels within the body, and this is described in the labeling of FDA cleared approved genetic test and FDA approved medications.”
![Page 25: Novel Treatments for Mood Disorders · Novel Treatments for Mood Disorders Michael E. Henry, MD Medical Director Bipolar Clinic and Research Program Director Somatic Therapy Massachusetts](https://reader033.fdocuments.net/reader033/viewer/2022050307/5f6f931ed7321c30e52c4fe2/html5/thumbnails/25.jpg)
www.mghcme.org
Inflammatory Cytokines
HPA Axis
BDNF Monoamine reuptake
IDO
Depression Adapted from Nekovarova T. et al., Front Behav Neurosci 2014; 8:99 epub
Inflammation and Depression
![Page 26: Novel Treatments for Mood Disorders · Novel Treatments for Mood Disorders Michael E. Henry, MD Medical Director Bipolar Clinic and Research Program Director Somatic Therapy Massachusetts](https://reader033.fdocuments.net/reader033/viewer/2022050307/5f6f931ed7321c30e52c4fe2/html5/thumbnails/26.jpg)
www.mghcme.org
Weight Loss/Obesity
◼Obesity associated with depression and poor quality of life
◼Weight loss associated with improved depression, quality of life., and cognition
- Exercise v Diet
Daumit et al. N Engl J Med. 2013; Napoli et al., Am J Clin Nutr. In press; Sylvia et
al. Int J Bipolar Disord. 2013; Vannucchi et al., J of Affect Disord. 2014.
![Page 27: Novel Treatments for Mood Disorders · Novel Treatments for Mood Disorders Michael E. Henry, MD Medical Director Bipolar Clinic and Research Program Director Somatic Therapy Massachusetts](https://reader033.fdocuments.net/reader033/viewer/2022050307/5f6f931ed7321c30e52c4fe2/html5/thumbnails/27.jpg)
www.mghcme.org
Inflammatory Markers and Depression
Meta Analysis 1967 - 2008
• Interleukin-1
d=0.35 (95%CI:0.03-0.67) p=0.03
• Interleukin-6
d=0.25 (95%CI:0.18-0.31) p<0.001
• C-Reactive Protein
d=0.15 (95%CI:0.10-0.21) p<0.001Howren M, et al. Psychosomatic Medicine 2009; 71:171-186.
![Page 28: Novel Treatments for Mood Disorders · Novel Treatments for Mood Disorders Michael E. Henry, MD Medical Director Bipolar Clinic and Research Program Director Somatic Therapy Massachusetts](https://reader033.fdocuments.net/reader033/viewer/2022050307/5f6f931ed7321c30e52c4fe2/html5/thumbnails/28.jpg)
www.mghcme.org
Minocycline
• 2 Trials in MDD
- Dean et al.(2017):
71 MDD, 36 randomized to minocycline.
Excluded if failed 3 or more antidepressant
trials
Week 12 MADRS -4, p = 0.624
- Husain et al. (2017):
41 MDD, 21 randomized to minocycline.
Included if failed at least 2 antidepressants
Week 12 HAM-D17 -18, d=-1.21 p<0.001.
![Page 29: Novel Treatments for Mood Disorders · Novel Treatments for Mood Disorders Michael E. Henry, MD Medical Director Bipolar Clinic and Research Program Director Somatic Therapy Massachusetts](https://reader033.fdocuments.net/reader033/viewer/2022050307/5f6f931ed7321c30e52c4fe2/html5/thumbnails/29.jpg)
www.mghcme.org
Celecoxib
• 4 RCT’s in MDD
• 200 -400 mg/day
• Sertraline, Fluoxetine, Reboxetine (p=0.058)
• OR: 6.607 (2.729, 15,994) z= 4.186, p<0.001.
• Bipolar: 1 RCT
• Antidepressant response rapid but short lived.
Husain MI. et al., Journal of Psychopharmacology 2017; 31:1137-48.Faridhoseini F et al., Human Psychopharmacology 2014; 29:216-213.
![Page 30: Novel Treatments for Mood Disorders · Novel Treatments for Mood Disorders Michael E. Henry, MD Medical Director Bipolar Clinic and Research Program Director Somatic Therapy Massachusetts](https://reader033.fdocuments.net/reader033/viewer/2022050307/5f6f931ed7321c30e52c4fe2/html5/thumbnails/30.jpg)
www.mghcme.org
Pioglitazone
• 1 RCT, 6 weeks
• BP-I
• 2015: Pioglitazone = 22; HDRS p=0.006
Rosenblat JD et al., Bipolar Disorder 2016; 18:89-101
![Page 31: Novel Treatments for Mood Disorders · Novel Treatments for Mood Disorders Michael E. Henry, MD Medical Director Bipolar Clinic and Research Program Director Somatic Therapy Massachusetts](https://reader033.fdocuments.net/reader033/viewer/2022050307/5f6f931ed7321c30e52c4fe2/html5/thumbnails/31.jpg)
www.mghcme.org
Infliximab
• Tumor Necrosis Factor (TNF)
• 60 subjects, 30 Infliximab, 3 infusions.
• No Difference in HAM-D scores.
• Sugestion that elevated CRP may define treatment responsive subtype.
Rosenblat JD et al., Bipolar Disorder 2016; 18:89-101.
![Page 32: Novel Treatments for Mood Disorders · Novel Treatments for Mood Disorders Michael E. Henry, MD Medical Director Bipolar Clinic and Research Program Director Somatic Therapy Massachusetts](https://reader033.fdocuments.net/reader033/viewer/2022050307/5f6f931ed7321c30e52c4fe2/html5/thumbnails/32.jpg)
www.mghcme.org
Purine Antagonists
• JNJ-54175446
- P2X7 receptor antagonist:Blocks IL 1B, IL18
- Gene in area identified as susceptible to
mood disorders
- Positive in animal models.
- Phase I
Neuroscience and Behavioral Reviews, 2018:192-205
![Page 33: Novel Treatments for Mood Disorders · Novel Treatments for Mood Disorders Michael E. Henry, MD Medical Director Bipolar Clinic and Research Program Director Somatic Therapy Massachusetts](https://reader033.fdocuments.net/reader033/viewer/2022050307/5f6f931ed7321c30e52c4fe2/html5/thumbnails/33.jpg)
www.mghcme.org
Botox
• Corrugator and Procerus muscles injections
• Facial nerve signaling shifts.
![Page 34: Novel Treatments for Mood Disorders · Novel Treatments for Mood Disorders Michael E. Henry, MD Medical Director Bipolar Clinic and Research Program Director Somatic Therapy Massachusetts](https://reader033.fdocuments.net/reader033/viewer/2022050307/5f6f931ed7321c30e52c4fe2/html5/thumbnails/34.jpg)
www.mghcme.org
Neuromodulation
Henry et al., J. ECT 2001
![Page 35: Novel Treatments for Mood Disorders · Novel Treatments for Mood Disorders Michael E. Henry, MD Medical Director Bipolar Clinic and Research Program Director Somatic Therapy Massachusetts](https://reader033.fdocuments.net/reader033/viewer/2022050307/5f6f931ed7321c30e52c4fe2/html5/thumbnails/35.jpg)
www.mghcme.org
Neuromodulation
• Deep TMS
• TMS: Theta burst
- 5 RCT’s, 221 subjects
- pooled RR 35.6% v 17.5% p=0.005 Berlim MT et al. , 2017.
• ECT- Multifocal Stimulation
• Magnetic Seizure and iLAST Therapy
![Page 36: Novel Treatments for Mood Disorders · Novel Treatments for Mood Disorders Michael E. Henry, MD Medical Director Bipolar Clinic and Research Program Director Somatic Therapy Massachusetts](https://reader033.fdocuments.net/reader033/viewer/2022050307/5f6f931ed7321c30e52c4fe2/html5/thumbnails/36.jpg)
www.mghcme.org
Conclusions
• Opiates and Glutamate/GABA are the predominant themes.
• Opiates will have to show abuse potential is not an issue.
• The immune/inflammation hypothesis of mood disorders may be directly targetable.
![Page 37: Novel Treatments for Mood Disorders · Novel Treatments for Mood Disorders Michael E. Henry, MD Medical Director Bipolar Clinic and Research Program Director Somatic Therapy Massachusetts](https://reader033.fdocuments.net/reader033/viewer/2022050307/5f6f931ed7321c30e52c4fe2/html5/thumbnails/37.jpg)
www.mghcme.org
References
1. Individual Company websites.
2. Clinical trials.gov
3. FDA.gov
4. Wikipedia; 9/23/2018 List of Investigational Antidepressants.
5. Mental Health Daily; 30+ New Antidepressants (2018): Drugs in Clinical Trials.